Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. develops and markets nutraceutical and wellness products for cognitive performance, brain recovery, pet vitality and weight management. Company news centers on the MyndSystem platform, including MyndMed for daytime cognitive support and MyndRenew for nighttime recovery support, as well as NeuroRush, PawPa Regen dog chews and Zeranovia.
Recurring updates cover product launches, direct-to-consumer availability, formulation positioning, pilot and dosage testing, athlete-safety testing for MyndMed, and expansion of pet-wellness and nootropic product lines.
BioAdaptives (BDPT) will ship its first commercial orders of XcellaraHeart next week, formally launching the Xcellara cellular wellness platform into commercial execution.
The company ties this milestone to its broader “Human Renewal” growth strategy, highlighting October 2026 as the targeted commercial introduction for XcellaraResilience, the second of a planned six-product Xcellara suite, with four additional formulations in active R&D. BioAdaptives reports full retirement of all debt held by its largest convertible commercial investor and states that CEO James E. Keener has voluntarily canceled and retired 43,250,000 common shares without compensation, reducing outstanding common shares. The company has also executed lock-up and leak-out agreements with major lenders and expanded its MyndSystem cognitive performance platform marketing by appointing Michael Bisping as a paid brand ambassador.
BioAdaptives (OTC:BDPT) announced that UFC Hall of Famer and former middleweight champion Michael Bisping has joined as a paid brand ambassador for the MyndSystem™ platform, focusing on the MyndMed™ daytime formula and MyndRenew™ nighttime powder within his performance routine.
The campaign will highlight Bisping’s personal use of MyndSystem™ alongside sleep, nutrition, and training for broadcasting, travel, podcasting, and acting. BioAdaptives also develops the Xcellara™ stem-cell–focused supplement line, supported by a human randomized, double-blind, placebo-controlled trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks without adverse blood-parameter effects.
BioAdaptives (OTC:BDPT) issued an update on its capital restructuring, executive equity and growth strategy as it launches the XcellaraHeart™ wellness formulation. The company previously had about 12 million common shares in public float, which it viewed as limiting trading liquidity.
To expand float, CEO James Keener converted his preferred stock into common, adding 43,250,000 shares. After liquidity objectives were met, he voluntarily canceled and retired those shares without compensation, removing them from issued and outstanding stock to reduce long-term overhang. BioAdaptives also executed lock-up and leak-out agreements with major lenders to regulate share sales and support market stability. Management is currently compensated exclusively in stock, with no cash salaries from operations. The company highlights its Xcellara™ base formula, supported by a human randomized, double-blind, placebo-controlled trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks, with no adverse effects reported on more than twenty blood parameters.
BioAdaptives (OTC:BDPT) announced the commercial launch and pre-order availability of XcellaraHeart™, a pharmaceutical-grade daily cardiovascular supplement and flagship of its new Xcellara™ cellular wellness platform of seven organ-targeted formulas. XcellaraHeart™ combines a clinically supported natural stem cell mobilizer with a molecular homing signal intended to direct regenerative cells toward cardiac tissue.
The base formula is backed by an IRB-approved, randomized, double-blind, placebo-controlled human trial showing a 268.8% average increase in circulating hematopoietic stem and progenitor cells after four weeks, with no adverse effects across more than 20 blood parameters. XcellaraHeart™ is priced at $159.95 per bottle with a 30-day money-back guarantee and free U.S. shipping, with pre-orders open August 12, 2026 and first shipments scheduled for August 26, 2026.
BioAdaptives (OTC:BDPT) outlined the scientific basis of its Xcellara™ “Supply and Direction” supplement platform, which combines clinically researched stem/progenitor cell mobilization with ingredients studied for tissue signaling pathways. The proprietary base formulation was evaluated in a randomized, double-blind, placebo-controlled human trial and showed an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with no adverse effects across more than 20 blood parameters, according to the company.
The “Supply” component focuses on raising measurable circulating stem and progenitor cells, while the “Direction” component adds natural compounds selected from published research on pathways such as the SDF-1α/CXCR4 chemokine axis. XcellaraHeart™, featuring Tanshinone IIA for cardiovascular-focused signaling support, is the first commercial product from this platform. BioAdaptives plans additional Xcellara™ formulas for joint, neurological, skin and other wellness targets, all built on the same clinically studied base plus tissue-specific signaling ingredients.
BioAdaptives (OTCID: BDPT) will open the commercial ordering window for XcellaraHeart™, the flagship product in its new Xcellara™ cellular wellness line, later this week via products.xcellara.com. This follows last week’s buyout and retirement of the company’s largest outstanding convertible commercial debt, which BioAdaptives says strengthens its capital structure and shifts focus to e-commerce execution and DTC revenue growth.
XcellaraHeart™ applies a novel “Supply & Direction” model to support natural cardiovascular repair mechanisms, and is based on the Xcellara™ platform. According to BioAdaptives, its Xcellara™ base formula is supported by a randomized, double-blind, placebo-controlled human clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on over twenty blood parameters. Additional targeted formulations—XcellaraOsteo™, XcellaraNeuro™, and XcellaraDerm™—are planned for late 2026.
BioAdaptives (OTC: BDPT) announced it has retired its largest convertible commercial investor, eliminating related convertible debt and equity overhang that had exerted selling pressure on its stock. The company said this move protects its capital structure from near‑term dilution via conversions and reflects a shift toward non‑dilutive funding and a strengthening balance sheet.
Management links the timing to the August launch of XcellaraHeart™, the first targeted product on the Xcellara™ cellular wellness platform, and expects equity value to be driven more by market demand and operating results. BioAdaptives also highlights human clinical data for its Xcellara™ base formula, reporting a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on over twenty blood parameters.
BioAdaptives (OTC: BDPT) announced an expanded e-commerce and direct-to-consumer footprint for its MyndSystem™ nootropic platform, following digital upgrades and a new subscription model at MyndSystem.com. According to BioAdaptives, these changes have driven higher online conversion rates and repeat customer acquisition, supporting recurring DTC revenue.
The WADA-compliant, stimulant-free MyndSystem suite includes MyndMed™ for daytime cognitive support and MyndRenew™ for nighttime brain restoration, aligned with circadian rhythms. The company also remains on track to launch its Xcellara™ cellular wellness platform in early August, aiming to broaden brand reach and revenue sources through 2026.
BioAdaptives develops the Xcellara stem cell mobilization line. According to the company, its flagship Xcellara base formula showed a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks in a randomized, double-blind, placebo-controlled human trial, with no adverse effects across more than twenty blood parameters.
BioAdaptives (OTC: BDPT) announced completion of its commercial manufacturing and logistics supply chain, positioning the company to begin rolling out its next-generation wellness platforms starting next month. Over the past quarter, BioAdaptives secured standardized, high-quality raw materials and partnered with GMP-compliant manufacturing facilities to support anticipated demand.
The company is preparing launches for its MyndSystem cognitive performance platform, comprising MyndMed for daytime focus and memory and MyndRenew for overnight neurological recovery, and its Xcellara cellular wellness platform, which supports natural stem cell mobilization and is backed by human, double-blind, placebo-controlled clinical data. BioAdaptives plans to release detailed product specifications, launch timelines, and scientific dossiers in the coming weeks.
BioAdaptives (OTC: BDPT) detailed the scientific strategy for its Xcellara™ cellular wellness platform ahead of the planned August 1, 2026 launch of XcellaraHeart™. The platform is built on two pillars: stem cell “Supply” via a clinically studied mobilization base and “Direction” through tissue‑specific signaling support.
The Xcellara™ base was evaluated in a human randomized controlled trial, reporting an average 268.8% increase in circulating stem/progenitor‑type cells. Direction is pursued by pairing this base with ingredients that support natural signaling pathways such as the SDF‑1α/CXCR4 axis. XcellaraHeart™ combines the base with Tanshinone IIA, a Danshen‑derived compound studied in cardiovascular research for its effects on this pathway. BioAdaptives plans additional Xcellara™ derivatives across wellness areas including joint, skin, nerve, cognitive and metabolic support, introduced on a regular cadence.